Analysis on the survival status and influencing factors of HIV/AIDS: a retrospective cohort study from 2000 to 2021 in Nanjing, China

XU Yuanyuan; LI Xiaoshan; WANG Jingwen; QIU Beibei; WU Sushu; LI Xin; SHI Hongjie; ZHU Zhengping

doi:10.16462/j.cnki.zhjbkz.2024.12.012

Volume 28 Issue 12

Dec. 2024

Turn off MathJax

Article Contents

Article Navigation > CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION > 2024 > 28(12): 1439-1445

XU Yuanyuan, LI Xiaoshan, WANG Jingwen, QIU Beibei, WU Sushu, LI Xin, SHI Hongjie, ZHU Zhengping. Analysis on the survival status and influencing factors of HIV/AIDS: a retrospective cohort study from 2000 to 2021 in Nanjing, China[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2024, 28(12): 1439-1445. doi: 10.16462/j.cnki.zhjbkz.2024.12.012

Citation:

XU Yuanyuan, LI Xiaoshan, WANG Jingwen, QIU Beibei, WU Sushu, LI Xin, SHI Hongjie, ZHU Zhengping. Analysis on the survival status and influencing factors of HIV/AIDS: a retrospective cohort study from 2000 to 2021 in Nanjing, China[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2024, 28(12): 1439-1445. doi: 10.16462/j.cnki.zhjbkz.2024.12.012

Citation:

XU Yuanyuan, LI Xiaoshan, WANG Jingwen, QIU Beibei, WU Sushu, LI Xin, SHI Hongjie, ZHU Zhengping. Analysis on the survival status and influencing factors of HIV/AIDS: a retrospective cohort study from 2000 to 2021 in Nanjing, China[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2024, 28(12): 1439-1445. doi: 10.16462/j.cnki.zhjbkz.2024.12.012

PDF( 2602 KB)

Analysis on the survival status and influencing factors of HIV/AIDS: a retrospective cohort study from 2000 to 2021 in Nanjing, China

doi: 10.16462/j.cnki.zhjbkz.2024.12.012

1.
Department of AIDS/STD Control and Prevention, Nanjing Municipal Center for Disease Control and Prevention, Nanjing 210003, China
2.
Department of Lung Transplant Center, Nanjing Medical University Affiliated Wuxi People′s Hospital, Wuxi 214023, China
3.
Department of Chronic Infectious Disease Control and Prevention, Nanjing Municipal Center for Disease Control and Prevention, Nanjing 210003, China

Funds:

National Natural Science Foundation of China 82103896

Jiangsu Province Social Science Application Research Excellent Engineering projects 23SYC-007

Nanjing Medical Science and Technology Development Project ZKX23059

Nanjing Medical Science and Technology Development Project YKK23192

Nanjing Medical University Nanjing Institute of Public Health Strengthening Project NQJ2301

Nanjing CDC Young Talents Research and Development Team Project NPY2307

More Information

Corresponding author: ZHU Zhengping, E-mail: zzp@njcdc.cn
Received Date: 2023-08-16
Rev Recd Date: 2024-06-14

Available Online: 2025-01-24

Publish Date: 2024-12-10

Abstract

Abstract

Objective To investigate the survival status and influencing factors of human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS) (HIV/AIDS) patients in Nanjing. Methods The retrospective cohort study of newly diagnosed HIV was conducted in Nanjing and used citywide data from the HIV/AIDS Comprehensive Information Management System from 2000 to 2021. Kaplan-Meier and cox proportional hazard regression method were used to draw the survival curve and analyze the factors associated with AIDS-related deaths, respectively. Results Among 5 903 HIV/AIDS cases, the AIDS-related mortality was 0.93 per 100 person-years and the cumulative survival rates at 1, 5, 10, and 22 years were 97.2%, 95.3%, 92.9%, and 90.0%, respectively. Multivariate analysis revealed that compared to untreated HIV/AIDS, the earlier the initiation of antiretroviral therapy (ART) after diagnosis, the lower the AIDS-related death risk. The HIV/AIDS with a baseline viral load (VL) ≥80 000 copies/mL had 6.54 times higher AIDS-related death risk than those with VL < 20 000 copies/mL. Compared to the first CD4 count before ART < 200 cells/μL, the higher the CD4 level, the lower the AIDS related death risk. ART was more effective in prolonging survival time among those with first CD4 count before ART < 200 cells/μL. Conclusions The AIDS-related mortality of HIV/AIDS is low in Nanjing. Early diagnosis, low baseline VL and rapid initiation of ART are protective factors for AIDS-related death. Therefore, on the basis of promoting the early diagnosis of HIV, we should strengthen the baseline monitoring of VL, optimize the follow-up management process to promote rapid ART, so as to further reduce the risk of AIDS-related death.
- Human immunodeficiency virus,
- Acquired immune deficiency syndrome,
- Antiretroviral therapy,
- Survival time,
- Mortality,
- Risk factor

FullText(HTML)

References(17)

References

[1]	UNAIDS. Global HIV & AIDS statistics - fact sheet- key populations[EB/OL]. (2023-06-13)[2023-09-01]. https://www.unaids.org/en/resources/fact-sheet.
[2]	Zhu ZP, Xu YY, Wu SS, et al. Survival and risk factors associated with mortality in people living with HIV from 2005 to 2018 in Nanjing, China[J]. Front Public Health, 2022, 10: 989127. DOI: 10.3389/fpubh.2022.989127.
[3]	Feng S, Zhu ZR, Yang PJ, et al. A comparative analysis on characteristics and mortalities of four key transmission populations on antiretroviral therapy: a retrospective cohort study in northwest China[J]. BMC Infect Dis, 2022, 22(1): 299. DOI: 10.1186/s12879-022-07281-x.
[4]	Ye L, Sun XW, Li YP, et al. Survival analysis of antiretroviral treatment for PLWH in Sichuan Province, China, 2003-2022: a large retrospective cohort study[J]. Infect Drug Resist, 2024, 17: 3133-3143. DOI: 10.2147/IDR.S463262.
[5]	曹文杰, 姚永明, 韦薇, 等. 贵州省1995―2018年HIV/AIDS生存时间及其影响因素分析[J]. 中华流行病学杂志, 2020, 41(4): 557-561. DOI: 10.3760/cma.j.cn112338-20190604-00395. Cao WJ, Yao YM, Wei W, et al. Survival time and related factors on HIV/AIDS patients in Guizhou Province from 1995 to 2018[J]. Chin J Epidemiol, 2020, 41(4): 557-561. DOI: 10.3760/cma.j.cn112338-20190604-00395.
[6]	付丽茹, 肖民扬, 贾曼红, 等. 云南省1989―2021年报告HIV/AIDS生存时间及影响因素分析[J]. 中华流行病学杂志, 2023, 44(6): 960-965. DOI: 10.3760/cma.j.cn112338-20221019-00890. Fu LR, Xiao MY, Jia MH, et al. Analysis on survival time and influencing factors among reported HIV/AIDS in Yunnan Province, 1989-2021[J]. Chin J Epidemiol, 2023, 44(6): 960-965. DOI: 10.3760/cma.j.cn112338-20221019-00890.
[7]	吴杨昊天, 冯才碧, 陈航, 等. 泸州市2010―2019年HIV/AIDS患者生存时间及影响因素分析[J]. 中华疾病控制杂志, 2021, 25(12): 1414-1419, 1425. DOI: 10.16462/j.cnki.zhjbkz.2021.12.010. Wu Y, Feng CB, Chen H, et al. Analysis of survival and its related factors of HIV/AIDS patient in Luzhou, 2010-2019[J]. Chin J Dis Control Prev, 2021, 25(12): 1414-1419, 1425. DOI: 10.16462/j.cnki.zhjbkz.2021.12.010.
[8]	Zhao Y, Wu ZY, McGoogan JM, et al. Immediate antiretroviral therapy decreases mortality among patients with high CD4 counts in China: a nationwide, retrospective cohort study[J]. Clin Infect Dis, 2018, 66(5): 727-734. DOI: 10.1093/cid/cix878.
[9]	Zhao Y, Wu Z, Mcgoogan J M, et al. Nationwide cohort study of antiretroviral therapy timing: treatment dropout and virological failure in China, 2011-2015[J]. Clin Infect Dis, 2019, 68(1): 43-50. DOI: 10.1093/cid/ciy400.
[10]	Bacon O, Chin J, Cohen SE, et al. Decreased time from human immunodeficiency virus diagnosis to care, antiretroviral therapy initiation, and virologic suppression during the citywide RAPID initiative in San Francisco[J]. Clin Infect Dis, 2021, 73(1): e122-e128. DOI: 10.1093/cid/ciaa620.
[11]	Muscatello A, Nozza S, Fabbiani M, et al. Enhanced immunological recovery with early start of antiretroviral therapy during acute or early HIV infection-results of Italian network of ACuTe HIV InfectiON (INACTION) retrospective study[J]. Pathog Immun, 2020, 5(1): 8-33. DOI: 10.20411/pai.v5i1.341.
[12]	Shoko C, Chikobvu D, Bessong PO. Effects of antiretroviral therapy on CD4⁺cell count, HIV viral load and death in a South African cohort: a modelling study[J]. Pak J Biol Sci, 2020, 23(4): 542-551. DOI: 10.3923/pjbs.2020.542.551.
[13]	Zhou C, Zhang W, Lu RR, et al. Higher risk of mortality and virologic failure in HIV-infected patients with high viral load at antiretroviral therapy initiation: an observational cohort study in Chongqing, China[J]. Front Public Health, 2022, 10: 800839. DOI: 10.3389/fpubh.2022.800839.
[14]	Dessie ZG, Zewotir T, Mwambi H, et al. Modelling of viral load dynamics and CD4 cell count progression in an antiretroviral naive cohort: using a joint linear mixed and multistate Markov model[J]. BMC Infect Dis, 2020, 20(1): 246. DOI: 10.1186/s12879-020-04972-1.
[15]	Ang LW, Toh MPHS, Wong CS, et al. Short-term mortality from HIV-infected persons diagnosed from 2012 to 2016: impact of iate diagnosis of HIV infection[J]. Medicine, 2021, 100(26): e26507. DOI: 10.1097/MD.0000000000026507.
[16]	Mohammadi Y, Mirzaei M, Shirmohammadi-Khorram N, et al. Identifying risk factors for late HIV diagnosis and survival analysis of people living with HIV/AIDS in Iran (1987-2016)[J]. BMC Infect Dis, 2021, 21(1): 390. DOI: 10.1186/s12879-021-06100-z.
[17]	Sun CQ, Li JJ, Liu XY, et al. HIV/AIDS late presentation and its associated factors in China from 2010 to 2020: a systematic review and Meta-analysis[J]. AIDS Res Ther, 2021, 18(1): 96. DOI: 10.1186/s12981-021-00415-2.